Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

This study is currently recruiting participants.
Verified by National Cancer Institute (NCI) August 2007

Sponsors and Collaborators:

North Central Cancer Treatment GroupNational Cancer Institute (NCI)

Information provided by:

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:

NCT00459862

Purpose

RATIONALE: Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying the side effects and how well pazopanib works in treating patients with malignant pleural mesothelioma.

Condition

Intervention

Phase

Malignant Mesothelioma

 Drug: pazopanib hydrochloride
 Procedure: anti-cytokine therapy
 Procedure: antiangiogenesis therapy
 Procedure: biological markers
 Procedure: biological therapy
 Procedure: diagnostic test
 Procedure: enzyme inhibitor therapy
 Procedure: growth factor antagonist therapy
 Procedure: protein tyrosine kinase inhibitor therapy

Phase II

MedlinePlus related topics:  Cancer;   Mesothelioma
Genetics Home Reference related topics:  Cancer

Study Type: Interventional
Study Design: Treatment, Open Label

Official Title: Phase II Study of GW786034 in Patients With Malignant Pleural Mesothelioma

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:

  • Proportion of patients who are progression-free at 6 months

Secondary Outcome Measures:

  • Response to treatment

  • Overall survival

  • Progression-free survival

  • Duration of response

  • Time to treatment failure

  • Toxicity

  • Tumor markers of angiogenesis


Total Enrollment:  55

Study start: March 2007

OBJECTIVES:

Primary

  • Determine the effect of pazopanib hydrochloride on the proportion of patients with malignant pleural mesothelioma who are progression-free at 6 months based on the RECIST criteria.

  • Determine the clinical toxicities of this drug in this patient population.

Secondary

  • Determine the objective tumor response status in these patients as measured by the RECIST criteria or the modified RECIST criteria.

  • Determine the response rate in patients treated with this drug.

  • Determine the effect of this drug on overall survival and time to progression in these patients.

  • Assess predictive markers of activity of this drug in these patients.

  • Assess serologic markers of target inhibition by this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

Blood is collected at baseline and prior to each course of therapy and analyzed for markers of angiogenesis.

After completion of study therapy, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed malignant pleural mesothelioma

    • Measurable disease

    • No progressive disease inside or outside of any prior radiation field

  • No symptomatic, untreated, or uncontrolled CNS metastases

    • Patients with CNS metastases treated with whole brain radiation (WBRT) may be enrolled after completion of WBRT

      • Patients may begin study therapy as early as the next day after completion of WBRT

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2

  • Life expectancy ≥ 12 weeks

  • ANC ≥1,500/mm³

  • Platelet count ≥ 100,000/mm³

  • WBC ≥ 3,000/mm³

  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)

  • AST and ALT ≤ 2.5 times ULN

  • Alkaline phosphatase ≤ 2.5 times ULN

  • Creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 mL/min

  • Proteinuria ≤ 1+ on 2 consecutive dipsticks taken ≥ 1 week apart

  • PT/INR/PTT ≤ 1.2 times ULN

  • Not pregnant or nursing

  • Negative pregnancy test

  • Fertile patients must use effective nonhormonal contraception

  • No uncontrolled infection

  • No uncontrolled blood pressure (BP) (defined as systolic BP > 140 mm Hg and/or diastolic BP > 90 mm Hg in spite of adequate anti-hypertensive therapy)

  • No condition that impairs ability to swallow and retain study drug tablets including, but not limited to, any of the following:

    • Gastrointestinal tract disease resulting in an inability to take oral medication

    • Requirement for IV alimentation

    • Prior surgical procedures affecting absorption

    • Active peptic ulcer disease

  • No other severe underlying disease that, in the judgment of the investigator, would limit study compliance

  • No other primary malignancy except for carcinoma in situ of the cervix or nonmelanomatous skin cancer, unless that prior malignancy was diagnosed and definitively treated ≥ 5 years ago with no subsequent evidence of recurrence

    • Patients with a history of low-grade (Gleason score ≤ 6) localized prostate cancer are eligible even if diagnosed within the past 5 years

  • No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents used in the study

  • None of the following concurrent severe and/or uncontrolled medical conditions:

    • Serious or nonhealing wound, ulcer, or bone fracture

    • Abdominal fistula, diverticulosis, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days

    • Poorly controlled diabetes

    • Interstitial pneumonia

    • Extensive and symptomatic interstitial fibrosis of the lung

  • No cardiovascular illness or complication, including any of the following:

    • Any history of cerebrovascular accident within the past 6 months

    • History of myocardial infarction (prior electrocardiographic evidence of myocardial injury)

    • History of cardiac arrhythmia (prior electrocardiographic evidence of abnormal heart rhythm)

    • Admission for unstable angina

    • Cardiac angioplasty or stenting within the past 12 months

    • NYHA class III-IV heart failure

      • Asymptomatic NYHA class II heart failure allowed

    • QTc prolongation (defined as a QTc interval ≥ 500 msecs) or other significant electrocardiogram abnormalities

    • Venous thrombosis within the past 12 weeks

  • No symptomatic, untreated, or uncontrolled seizure disorder

  • No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit study compliance

  • No significant traumatic injury within the past 4 weeks

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics

  • No more than 1 prior systemic therapy for malignant pleural mesothelioma

  • No ancillary therapy considered investigational within the past 4 weeks

  • No major surgery (i.e., laparotomy) or open biopsy within the past 4 weeks*

  • No minor surgery within the past 2 weeks*

  • Prior palliative radiotherapy allowed

    • No prior palliative radiotherapy to the chest except for a maximum of 3 fractions of radiotherapy for superior vena cava syndrome

  • No concurrent therapeutic warfarin

    • Low molecular-weight heparin or prophylactic low-dose warfarin allowed

  • No other concurrent chemotherapy, immunotherapy, hormonal therapy, or radiotherapy

  • No concurrent medications that act through the CYP450 system

  • No concurrent combination antiretroviral therapy for HIV-positive patients NOTE: *Insertion of a vascular access device is not considered major or minor surgery

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00459862


United States, Illinois
      BroMenn Regional Medical Center, Normal,  Illinois,  61761,  United States; Recruiting John W. Kugler, MD  309-243-3000 

      Cancer Treatment Center at Pekin Hospital, Pekin,  Illinois,  61554,  United States; Recruiting , John W. Kugler, MD  309-243-3000 

      Carle Cancer Center at Carle Foundation Hospital, Urbana,  Illinois,  61801,  United States; Recruiting

Clinical Trials Office - Carle Cancer Center at Carle Foundati  800-446-5532 

      CCOP - Carle Cancer Center, Urbana,  Illinois,  61801,  United States; Recruiting

Clinical Trials Office - CCOP - Carle Cancer Center  800-446-5532 

      CCOP - Illinois Oncology Research Association, Peoria,  Illinois,  61615,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Community Cancer Center, Normal,  Illinois,  61761,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Community Hospital of Ottawa, Ottawa,  Illinois,  61350,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Eureka Community Hospital, Eureka,  Illinois,  61530,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Galesburg Clinic, PC, Galesburg,  Illinois,  61401,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Galesburg Cottage Hospital, Galesburg,  Illinois,  61401,  United States; Recruiting

John W. Kugler, MD  309-243-3000 


      Graham Hospital, Canton,  Illinois,  61520,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Hopedale Medical Complex, Hopedale,  Illinois,  61747,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Illinois Valley Community Hospital, Peru,  Illinois,  61354,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Joliet Oncology-Hematology Associates, Limited - West, Joliet,  Illinois,  60435,  United States; Recruiting

Kendrith M. Rowland, MD  217-383-3010 

      Kewanee Hospital, Kewanee,  Illinois,  61443,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Mason District Hospital, Havana,  Illinois,  62644,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      McDonough District Hospital, Macomb,  Illinois,  61455,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Memorial Hospital, Carthage,  Illinois,  62321,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Methodist Medical Center of Illinois, Peoria,  Illinois,  61636,  United States; Recruiting

Clinical Trials Office - Methodist Medical Center of Illinois  309-243-3000 

      Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa,  Illinois,  61350,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria,  Illinois,  61615,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      OSF St. Francis Medical Center, Peoria,  Illinois,  61637,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Perry Memorial Hospital, Princeton,  Illinois,  61356,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Proctor Hospital, Peoria,  Illinois,  61614,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      Rush-Copley Cancer Care Center, Aurora,  Illinois,  60507,  United States; Recruiting

Kendrith M. Rowland, MD  217-383-3010 

      St. Joseph Medical Center, Bloomington,  Illinois,  61701,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

      St. Margaret's Hospital, Spring Valley,  Illinois,  61362,  United States; Recruiting

John W. Kugler, MD  309-243-3000 

United States, Indiana
      Reid Hospital & Health Care Services, Richmond,  Indiana,  47374,  United States; Recruiting

Howard M. Gross, MD  765-983-3000 

      Saint Anthony Memorial Health Centers, Michigan City,  Indiana,  46360,  United States; Recruiting

Kendrith M. Rowland, MD  217-383-3010 

      St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove,  Indiana,  46107,  United States; Recruiting

Howard M. Gross, MD  317-787-3311 

United States, Iowa
      CCOP - Iowa Oncology Research Association, Des Moines,  Iowa,  50309,  United States; Recruiting

Roscoe F. Morton, MD, FACP  515-244-7586 

      Cedar Rapids Oncology Associates, Cedar Rapids,  Iowa,  52403,  United States; Recruiting

Clinical Trials Office - Cedar Rapids Oncology Associates  319-363-2690 

      John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines,  Iowa,  50316,  United States; Recruiting

Clinical Trials Office - John Stoddard Cancer Center at Iowa L  515-241-8704 

      John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines,  Iowa,  50309,  United States; Recruiting

Clinical Trials Office - John Stoddard Cancer Center at Iowa M  515-241-6727 

      Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines,  Iowa,  50309,  United States; Recruiting

Roscoe F. Morton, MD, FACP  515-244-7586 

      Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines,  Iowa,  50314,  United States; Recruiting

Roscoe F. Morton, MD, FACP  515-244-7586 

      Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines,  Iowa,  50314,  United States; Recruiting

Roscoe F. Morton, MD, FACP  515-244-7586 

      Mercy Capitol Hospital, Des Moines,  Iowa,  50307,  United States; Recruiting

Roscoe F. Morton, MD, FACP  515-244-7586 

      Mercy Medical Center - Sioux City, Sioux City,  Iowa,  51104,  United States; Recruiting

Donald B. Wender, MD, PhD  712-252-9326 

      Siouxland Hematology-Oncology Associates, LLP, Sioux City,  Iowa,  51101,  United States; Recruiting

Donald B. Wender, MD, PhD  712-252-9326 

      St. Luke's Regional Medical Center, Sioux City,  Iowa,  51104,  United States; Recruiting

Donald B. Wender, MD, PhD  712-252-9326 

United States, Kansas
      Associates in Womens Health, PA - North Review, Wichita,  Kansas,  67203,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Kingman, Kingman,  Kansas,  67068,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Wichita, Wichita,  Kansas,  67214,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Chanute, Chanute,  Kansas,  66720,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Dodge City, Dodge City,  Kansas,  67801,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - El Dorado, El Dorado,  Kansas,  67042,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Medical Arts Tower, Wichita,  Kansas,  67208,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Newton, Newton,  Kansas,  67114,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Parsons, Parsons,  Kansas,  67357,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Pratt, Pratt,  Kansas,  67124,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Salina, Salina,  Kansas,  67042,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Wellington, Wellington,  Kansas,  67152,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Cancer Center of Kansas, PA - Winfield, Winfield,  Kansas,  67156,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      CCOP - Wichita, Wichita,  Kansas,  67214,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Southwest Medical Center, Liberal,  Kansas,  67901,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

      Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita,  Kansas,  67214,  United States; Recruiting

Shaker R. Dakhil, MD, FACP  316-262-4467 

United States, Michigan
      Dickinson County Healthcare System, Iron Mountain,  Michigan,  49801,  United States; Recruiting

Anthony J. Jaslowski, MD, FACP  920-884-3135 

      Green Bay Oncology, Limited - Escanaba, Escanaba,  Michigan,  49431,  United States; Recruiting

Anthony J. Jaslowski, MD, FACP  920-884-3135 

United States, Minnesota
      CCOP - Metro-Minnesota, Saint Louis Park,  Minnesota,  55416,  United States; Recruiting

Patrick J. Flynn, MD  612-863-8585 

      Fairview Ridges Hospital, Burnsville,  Minnesota,  55337,  United States; Recruiting

Patrick J. Flynn, MD  612-863-8585 

      Fairview Southdale Hospital, Edina,  Minnesota,  55435,  United States; Recruiting

Clinical Trials Office - Fairview Southdale Hospital  612-625-3650 

      HealthEast Cancer Care at St. John's Hospital, Maplewood,  Minnesota,  55109,  United States; Recruiting

Daniel M. Anderson  651-232-7970 

      HealthEast Cancer Care at St. Joseph's Hospital, St Paul,  Minnesota,  55102,  United States; Recruiting

Daniel M. Anderson  651-232-7970 

      HealthEast Cancer Care at Woodwinds Health Campus, Woodbury,  Minnesota,  55125,  United States; Recruiting

Daniel M. Anderson  651-232-7970 

      Hennepin County Medical Center - Minneapolis, Minneapolis,  Minnesota,  55415,  United States; Recruiting

Clinical Trials Office - Hennepin County Medical Center - Minn  612-873-5911 

      Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale,  Minnesota,  55422-2900,  United States; Recruiting

Clinical Trials Office - Hubert H. Humphrey Cancer Center at N  763-520-1893 

      Hutchinson Area Health Care, Hutchinson,  Minnesota,  55350,  United States; Recruiting

Daniel M. Anderson  320-234-5000 

      Mayo Clinic Cancer Center, Rochester,  Minnesota,  55905,  United States; Recruiting

Clinical Trials Office - Mayo Clinic Cancer Center  507-538-7623 

      Meeker County Memorial Hospital, Lichfield,  Minnesota,  55355,  United States; Recruiting

Clinical Trials Office - Meeker County Memorial Hospital  320-693-4520 

      Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids,  Minnesota,  55433,  United States; Recruiting

Patrick J. Flynn, MD  612-863-8585 

      Mercy and Unity Cancer Center at Unity Hospital, Fridley,  Minnesota,  55432,  United States; Recruiting

Patrick J. Flynn, MD  612-863-8585 

      Minnesota Oncology Hematology, PA - Maplewood, Maplewood,  Minnesota,  55109,  United States; Recruiting

Patrick J. Flynn, MD  612-863-8585 

      Minnesota Oncology Hematology, PA - Woodbury, Woodbury,  Minnesota,  55125,  United States; Recruiting

Patrick J. Flynn, MD  612-863-8585 

      Park Nicollet Cancer Center, St. Louis Park,  Minnesota,  55416,  United States; Recruiting

Patrick J. Flynn, MD  612-863-8585 

      Regions Hospital Cancer Care Center, St. Paul,  Minnesota,  55101,  United States; Recruiting

Clinical Trials Office - Regions Hospital Cancer Care Center  651-254-1517 

      Ridgeview Medical Center, Waconia,  Minnesota,  55387,  United States; Recruiting

Patrick J. Flynn, MD  612-863-8585 

      St. Francis Cancer Center at St. Francis Medical Center, Shakopee,  Minnesota,  55379,  United States; Recruiting

Daniel M. Anderson  952-403-2031 

      United Hospital, St. Paul,  Minnesota,  55102,  United States; Recruiting

Patrick J. Flynn, MD  612-863-8585 

      Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis,  Minnesota,  55407,  United States; Recruiting

Clinical Trials Office - Virginia Piper Cancer Institute  612-863-5654 

United States, Montana
      Billings Clinic - Downtown, Billings,  Montana,  59107-7000,  United States; Recruiting

Clinical Trials Office - Billings Clinic - Downtown  800-996-2663    research@billingsclinic.org 

      Bozeman Deaconess Cancer Center, Bozeman,  Montana,  59715,  United States; Recruiting

Benjamin T. Marchello, MD  406-585-5000 

      CCOP - Montana Cancer Consortium, Billings,  Montana,  59101,  United States; Recruiting

Benjamin T. Marchello, MD  406-259-2245 

      Community Medical Center, Missoula,  Montana,  59801,  United States; Recruiting

Benjamin T. Marchello, MD  406-728-4100 

      Glacier Oncology, PLLC, Kalispell,  Montana,  59901,  United States; Recruiting

Benjamin T. Marchello, MD  406-752-7600 

      Great Falls Clinic - Main Facility, Great Falls,  Montana,  59405,  United States; Recruiting

Benjamin T. Marchello, MD  406-454-2171 

      Guardian Oncology and Center for Wellness, Missoula,  Montana,  59804,  United States; Recruiting

Benjamin T. Marchello, MD  406-721-1118 

      Hematology-Oncology Centers of the Northern Rockies - Billings, Billings,  Montana,  59101,  United States; Recruiting

Benjamin T. Marchello, MD  406-238-6290 

      Kalispell Medical Oncology at KRMC, Kalispell,  Montana,  59901,  United States; Recruiting

Benjamin T. Marchello, MD  406-752-8900 

      Kalispell Regional Medical Center, Kalispell,  Montana,  59901,  United States; Recruiting

Benjamin T. Marchello, MD  406-752-5111 

      Great Falls,  Montana,  59405,  United States; Recruiting

Benjamin T. Marchello, MD

      Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula,  Montana,  59807,  United States; Recruiting

Clinical Trials Office - Montana Cancer Center at St. Patrick  406-329-7029 

      Montana Cancer Specialists at Montana Cancer Center, Missoula,  Montana,  59807-7877,  United States; Recruiting

Clinical Trials Office - Montana Cancer Specialists at Montana  406-238-6962 

      Northern Rockies Radiation Oncology Center, Billings,  Montana,  59101,  United States; Recruiting

Benjamin T. Marchello, MD  406-248-2212 

      St. James Healthcare Cancer Care, Butte,  Montana,  59701,  United States; Recruiting

Benjamin T. Marchello, MD  406-723-2500 

      St. Peter's Hospital, Helena,  Montana,  59601,  United States; Recruiting

Benjamin T. Marchello, MD  406-442-2480 

      St. Vincent Healthcare Cancer Care Services, Billings,  Montana,  59101,  United States; Recruiting

Benjamin T. Marchello, MD  406-657-7000 

United States, Nebraska
      Alegant Health Cancer Center at Bergan Mercy Medical Center, Omaha,  Nebraska,  68124,  United States; Recruiting

Clinical Trials Office - Alegant Health Cancer Center at Berge  402-398-6060 

      CCOP - Missouri Valley Cancer Consortium, Omaha,  Nebraska,  68106,  United States; Recruiting

Gamini S. Soori, MD, FACP, FRCP, MBA  402-393-3110 

      Creighton University Medical Center, Omaha,  Nebraska,  68131-2197,  United States; Recruiting

Clinical Trials Office - Creighton University Medical Center  402-280-4100 

      Immanuel Medical Center, Omaha,  Nebraska,  68122,  United States; Recruiting

Gamini S. Soori, MD, FACP, FRCP, MBA  402-393-3110 

United States, North Carolina
      Rutherford Hospital, Rutherfordton,  North Carolina,  28139,  United States; Recruiting

James D. Bearden, MD  864-560-6812 

United States, North Dakota
      Bismarck Cancer Center, Bismarck,  North Dakota,  58501,  United States; Recruiting

Edward J. Wos, DO  701-323-5741 

      Medcenter One Hospital Cancer Care Center, Bismarck,  North Dakota,  58501,  United States; Recruiting

Edward J. Wos, DO  701-323-5741 

      Mid Dakota Clinic, PC, Bismarck,  North Dakota,  58501,  United States; Recruiting

Clinical Trials Office - Mid Dakota Clinic, PC  701-530-6950 

      St. Alexius Medical Center Cancer Center, Bismarck,  North Dakota,  58502,  United States; Recruiting

Clinical Trials Office - St. Alexius Medical Center Cancer Cen  701-530-6950 

United States, Ohio
      Blanchard Valley Medical Associates, Findlay,  Ohio,  45840,  United States; Recruiting

Howard M. Gross, MD  419-424-0380 

      CCOP - Dayton, Dayton,  Ohio,  45429,  United States; Recruiting

Howard M. Gross, MD  937-395-8678 

      Charles F. Kettering Memorial Hospital, Kettering,  Ohio,  45429,  United States; Recruiting

Clinical Trials Office - Charles F. Kettering Memorial Hospita  937-298-3399 ext. 58868 

      David L. Rike Cancer Center at Miami Valley Hospital, Dayton,  Ohio,  45409,  United States; Recruiting

Clinical Trials Office - David L. Rike Cancer Center at Miami  937-208-2079 

      Good Samaritan Hospital, Dayton,  Ohio,  45406,  United States; Recruiting

Howard M. Gross, MD  937-278-2612 

      Grandview Hospital, Dayton,  Ohio,  45405,  United States; Recruiting

Howard M. Gross, MD  937-226-3200 

      Middletown Regional Hospital, Middletown,  Ohio,  45044,  United States; Recruiting

Howard M. Gross, MD  513-424-2111 

      Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia,  Ohio,  45385,  United States; Recruiting

Howard M. Gross, MD  937-352-2140 

      Samaritan North Cancer Care Center, Dayton,  Ohio,  45415,  United States; Recruiting

Howard M. Gross, MD  937-279-5800 

      UVMC Cancer Care Center at Upper Valley Medical Center, Troy,  Ohio,  45373-1300,  United States; Recruiting

Clinical Trials Office - UVMC Cancer Care Center at Upper Vall  937-440-4842 

      Veterans Affairs Medical Center - Dayton, Dayton,  Ohio,  45428,  United States; Recruiting

Howard M. Gross, MD  937-268-6511 

United States, Pennsylvania
      Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown,  Pennsylvania,  18105,  United States; Recruiting

Suresh G. Nair, MD  610-402-0500 

United States, South Carolina
      AnMed Cancer Center, Anderson,  South Carolina,  29621,  United States; Recruiting

Clinical Trials Office - AnMed Cancer Center  864-512-1000 

      CCOP - Upstate Carolina, Spartanburg,  South Carolina,  29303,  United States; Recruiting

Clinical Trials Office - CCOP - Upstate Carolina  800-486-5941 

      Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg,  South Carolina,  29303,  United States; Recruiting

Clinical Trials Office - Gibbs Regional Cancer Center at Spart  800-486-5941 

United States, South Dakota
      Rapid City Regional Hospital, Rapid City,  South Dakota,  57701,  United States; Recruiting

Richard C. Tenglin  605-719-2360 

United States, Wisconsin
      Bay Area Cancer Care Center at Bay Area Medical Center, Marinette,  Wisconsin,  54143,  United States; Recruiting

Anthony J. Jaslowski, MD, FACP  920-884-3135 

      Green Bay Oncology, Limited - Oconto Falls, Oconto Falls,  Wisconsin,  54154,  United States; Recruiting

Anthony J. Jaslowski, MD, FACP  920-884-3135 

      Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay,  Wisconsin,  54235,  United States; Recruiting

Anthony J. Jaslowski, MD, FACP  920-884-3135 

      Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay,  Wisconsin,  54303,  United States; Recruiting

Anthony J. Jaslowski, MD, FACP  920-884-3135 

      Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center, Green Bay,  Wisconsin,  54301-3526,  United States; Recruiting

Anthony J. Jaslowski, MD, FACP  920-884-3135 

      St. Mary's Hospital Medical Center - Green Bay, Green Bay,  Wisconsin,  54303,  United States; Recruiting

Anthony J. Jaslowski, MD, FACP  920-884-3135 

      St. Vincent Hospital Regional Cancer Center, Green Bay,  Wisconsin,  54307-3508,  United States; Recruiting

Clinical Trials Office - St. Vincent Hospital Regional Cancer  920-433-8889 

United States, Wyoming
      Welch Cancer Center at Sheridan Memorial Hospital, Sheridan,  Wyoming,  82801,  United States; Recruiting

Benjamin T. Marchello, MD  307-674-6022 

Study chairs or principal investigators

Julian Molina, MD, PhD,  Study Chair,  Mayo Clinic   
Nicholas F. Reuter, MD,  Coborn Cancer Center   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000539269; NCCTG-N0623
Last Updated:  September 5, 2007
Record first received:  April 11, 2007
ClinicalTrials.gov Identifier:  NCT00459862
Health Authority: Unspecified
ClinicalTrials.gov processed this record on September 20, 2007

Source: www.ClinicalTrials.gov